News Release: July 25, 2025
Indocyanine Green Price, Production, Latest News and Developments in 2025
The global market for Indocyanine Green (ICG) has experienced notable shifts in 2025, driven by demand from diagnostic imaging, surgical guidance applications, and growing uptake in the pharmaceutical and biotechnology sectors. Indocyanine green price trend and production news highlight the evolving landscape of this critical chemical, particularly in medical diagnostics. This year has witnessed changes in pricing, production capacities, and international trade routes, making it imperative to analyze the underlying developments and trends.
Indocyanine Green Price Trend in Past Five Years and Factors Impacting Price Movements
Over the past five years, Indocyanine Green price trends have shown moderate but steady fluctuations. In 2020, the average global price of Indocyanine Green stood at around $1,200/MT. By the end of 2021, the price saw an increase to $1,350/MT due to higher demand in healthcare applications post-COVID-19 pandemic. The sharp increase in diagnostic imaging and surgical procedures drove the growth in Indocyanine Green sales volume during this period.
In 2022, a moderate price rise was recorded with Indocyanine Green averaging $1,500/MT. Supply chain bottlenecks, particularly in the Asia-Pacific region due to prolonged lockdowns in China and other countries, led to a shortage of key raw materials, slightly pushing prices upward.
By 2023, the price increased further to approximately $1,700/MT. New regulations in Europe surrounding pharmaceutical-grade dyes increased compliance costs for manufacturers, adding to the overall production expenses. In parallel, the expansion of advanced surgical procedures in the U.S., Germany, and Japan added further upward pressure on Indocyanine Green price news globally.
In 2024, a more stabilized scenario was observed. Prices fluctuated around $1,750/MT as supply and demand reached a temporary balance. Increased Indocyanine Green production capacity in India and South Korea offset rising demand in Western markets, leading to a narrow range of price volatility.
As of 2025, the Indocyanine Green price news remains dynamic. A stronger push for minimally invasive surgeries in emerging economies, combined with rising R&D spending in fluorescence imaging, has placed Indocyanine Green at the center of clinical innovation. Current market indicators show that Indocyanine Green is trading at an average of $1,880/MT, marking a 7.4% increase from 2024.
Key factors impacting Indocyanine Green price trend include:
- Regulatory shifts in pharmaceutical ingredients
- Availability and cost of raw materials such as iodine-based compounds
- Advancements in fluorescence-guided surgery and photodynamic therapy
- Fluctuations in Indocyanine Green sales volume across continents
- Manufacturing scale efficiencies in Asia
The increasing demand across oncology, cardiovascular diagnostics, and liver function assessment segments is likely to support elevated pricing levels in the short-to-mid-term. However, new manufacturers entering the market from Southeast Asia and South America may eventually place downward pressure on prices as competition grows.
Indocyanine Green Price Trend Quarterly Update in $/MT (Estimated Quarterly Prices)
Based on current data and projections for 2025, below is the quarterly Indocyanine Green price update:
- Q1 2025: $1,820/MT
- Q2 2025: $1,870/MT
- Q3 2025: $1,880/MT
- Q4 2025: $1,950/MT
The increase from Q1 to Q4 reflects rising Indocyanine Green sales volume in North America and Europe, supported by hospital procurement surges and improved insurance coverage for image-guided procedures. In Q2, demand was partially restrained due to delays in procurement cycles in East Asia, but rebounded by Q3 with restocking and R&D usage.
Global Indocyanine Green Import-Export Business Overview
The global import-export landscape for Indocyanine Green is closely tied to pharmaceutical and medical device supply chains. Major producers include the United States, Germany, Japan, India, and South Korea, while key importers span across Southeast Asia, Latin America, Eastern Europe, and Africa.
North America continues to lead global Indocyanine Green consumption due to advanced healthcare infrastructure and high per capita spending on diagnostics. The U.S. alone accounts for over 35% of total global demand. Despite significant domestic production, the U.S. imports Indocyanine Green from Germany and Japan to meet high-quality pharmaceutical standards and urgent bulk requirements. The import volume surged in Q1 and Q2 2025 as U.S.-based firms scaled up purchases to meet clinical trial needs and imaging center contracts.
Europe has maintained a robust production base, with Germany being the largest exporter within the EU. Germany exports large volumes to France, Italy, the UK, and Eastern Europe. Post-Brexit trade policies have modestly altered Indocyanine Green supply flows into the UK, with direct imports from Japan and South Korea gaining traction.
Asia-Pacific is a dual-region of production and consumption. Japan remains a leading manufacturer, renowned for quality-controlled batches used in high-precision imaging systems. South Korea has emerged as a new production hub, increasing exports by nearly 15% in 2025 compared to 2024. India, with low-cost production capacity, is increasingly exporting Indocyanine Green to African and Middle Eastern countries. Its export volumes have expanded by over 20% YoY in 2025. Chinese consumption has risen as public hospitals upgrade diagnostic tools, but most of its supply is met through domestic manufacturers.
Middle East & Africa (MEA) is a rapidly growing market. The import dependency is high in this region. Countries like Saudi Arabia, UAE, and South Africa rely heavily on European and Indian suppliers. New bilateral trade agreements in 2025 have reduced import duties, allowing easier access to pharmaceutical-grade dyes including Indocyanine Green. This has directly contributed to growing Indocyanine Green sales volume in tertiary medical facilities in MEA.
Latin America imports nearly 80% of its Indocyanine Green requirements. Brazil, Mexico, and Argentina are major consumers, relying mainly on U.S. and Indian exporters. The rise in minimally invasive surgeries and optical diagnostics has triggered a 12% YoY increase in imports in 2025. However, local production remains minimal, offering a potential investment opportunity for global producers looking to expand.
Key trade developments in 2025 include:
- India-Japan Pharma Corridor: Accelerated shipping of Indocyanine Green to Southeast Asia and Oceania.
- U.S.–EU Regulatory Alignment: Eased pharmaceutical import protocols improving U.S. import flexibility from European suppliers.
- South Korea–Brazil Free Trade Pact: Slashed duties on pharmaceutical dyes, making Indocyanine Green more cost-effective for South American hospitals.
Trade volumes in 2025 have been buoyed by favorable customs policies, improved supply chain resilience, and increased regional healthcare budgets. While demand remains concentrated in developed nations, the fastest-growing markets are in Asia-Pacific (outside Japan), MEA, and Latin America.
Global exporters are now prioritizing compliance with strict GMP standards to meet evolving regulatory demands. This includes batch testing transparency, traceability, and sustainable packaging – all of which affect Indocyanine Green production and shipment volumes.
The Indocyanine Green price trend in trade is expected to maintain an upward trajectory as high-purity standards are increasingly required, particularly for surgical applications and medical imaging uses. Additionally, as patents around manufacturing techniques expire, generic competition may provide downward pressure on export prices by late 2026.
For more detailed analysis on Indocyanine Green price news, production, and regional market shares, visit https://datavagyanik.com/reports/indocyanine-green-market-size-production-sales-average-product-price-market-share-import-vs-export/ and request a sample today.
Indocyanine Green Production Trends by Geography
The global production of Indocyanine Green (ICG) has grown significantly in recent years, driven by increasing demand in medical diagnostics, image-guided surgeries, and research-based applications. In 2025, the production dynamics of Indocyanine Green show a clear shift toward Asia, with major capacity expansions, while North America and Europe continue to lead in terms of high-purity pharmaceutical-grade output. Here’s a geographical overview of key production trends.
United States
The U.S. remains one of the most significant producers of Indocyanine Green, catering primarily to domestic pharmaceutical and clinical needs. American manufacturers are known for high compliance with regulatory standards such as FDA and USP guidelines, making their products highly sought-after for critical applications like cardiovascular imaging, cancer diagnostics, and ophthalmology. In 2025, several mid-sized companies in the U.S. have expanded their production units to meet rising Indocyanine Green sales volume in hospitals and research institutes. However, the country faces cost pressures due to high manufacturing overhead and environmental regulations.
Germany
Germany is a prominent European hub for the production of Indocyanine Green. German companies supply both domestic and international markets with pharmaceutical-grade dye that meets stringent EU quality norms. Production here emphasizes small-batch precision manufacturing, ensuring consistent output and low impurity levels. In 2025, Germany has also been investing in green chemistry initiatives to lower the environmental impact of dye production. Most exports go to neighboring EU countries, the UK, and North America, with Germany being recognized for quality and reliability.
Japan
Japan has maintained its leadership position in the high-end segment of Indocyanine Green production. Japanese firms focus on producing ultra-pure grades used in precision diagnostics and high-resolution imaging systems. The domestic demand in Japan is robust due to widespread use in surgical procedures, liver function tests, and retinal angiography. In 2025, several Japanese companies have reported capacity expansion to accommodate exports to Southeast Asia and the Middle East. Japanese producers are also exploring proprietary formulations with enhanced stability and fluorescence intensity.
India
India is emerging as a key global supplier of Indocyanine Green, especially for cost-sensitive markets. Indian manufacturers benefit from lower production costs, access to skilled labor, and rapidly expanding chemical synthesis capabilities. In 2025, the country has scaled up both API-grade and research-grade ICG production. Most of the output is exported to Africa, the Middle East, and Latin America. Indian producers are also collaborating with contract manufacturing organizations to produce customized dye variants for OEMs and research institutions abroad.
South Korea
South Korea has gained a reputation for producing high-quality Indocyanine Green at competitive prices. In 2025, South Korean manufacturers have grown their production capacities to cater to the increasing demand from hospitals across Asia-Pacific. Companies in South Korea are investing in cleanroom facilities and R&D to develop improved versions of ICG with better fluorescence properties. The country’s proximity to key markets such as China, Southeast Asia, and Japan also gives it a logistical edge.
China
China has a growing footprint in the production of Indocyanine Green, largely for domestic consumption. The increasing use of diagnostic imaging tools in Chinese hospitals has created a surge in local demand. Chinese producers are focused on mass production rather than high-end pharmaceutical grades. However, in 2025, several Chinese chemical firms have upgraded their facilities to cater to international quality requirements, targeting exports to Eastern Europe and Africa. As China continues to modernize its chemical manufacturing sector, it is expected to play a more significant role in global ICG production.
Other Notable Regions
Brazil and Mexico are exploring domestic production to reduce dependency on imports, but the scale remains limited. These countries still rely heavily on the U.S. and India for supply. Similarly, countries in the Middle East and Africa are major importers rather than producers, though there is increasing interest in establishing local formulation and repackaging facilities.
In summary, the Indocyanine Green production landscape in 2025 is marked by regional specialization: high-end production in Japan and Germany, cost-efficient output in India and South Korea, and balanced production-consumption in the U.S. and China. The global supply chain for Indocyanine Green is robust but increasingly shaped by regional advantages, environmental policies, and technology innovation in synthetic dye chemistry.
Indocyanine Green Market Segmentation
Key Segments of the Indocyanine Green Market:
- By Application:
- Diagnostic Imaging
- Ophthalmic Procedures
- Oncology and Cancer Imaging
- Cardiovascular Imaging
- Liver Function Testing
- Neurosurgery
- Research and Development
- By End-User:
- Hospitals
- Diagnostic Centers
- Academic and Research Institutions
- Pharmaceutical Companies
- By Formulation:
- Lyophilized Powder
- Liquid Form
- By Purity Grade:
- Pharmaceutical Grade
- Research Grade
- Industrial Grade
- By Geography:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Detailed Segment Explanation
1. By Application
Among all application segments, diagnostic imaging holds the largest share of the Indocyanine Green market. In 2025, the increasing use of near-infrared fluorescence imaging in surgeries such as cancer resection, sentinel lymph node mapping, and vascular imaging has driven demand significantly. Indocyanine Green’s unique property of emitting near-infrared light after excitation makes it ideal for real-time intraoperative imaging.
Ophthalmic procedures form another strong application area, especially for retinal angiography. ICG angiography is widely adopted to detect abnormalities in choroidal vessels and is preferred over fluorescein in certain conditions.
Oncology is an emerging and rapidly expanding application, as Indocyanine Green is increasingly used in image-guided tumor removal. Its role in liver cancer surgeries, particularly for identifying metastases and ensuring clear margins, is a major growth driver.
Liver function testing using Indocyanine Green clearance methods is a standard diagnostic approach, especially in hepatology. It is gaining ground in both developed and developing nations.
Neurosurgery is also adopting ICG-guided imaging during aneurysm surgeries and arteriovenous malformation treatments. This specialized use is expected to grow with improvements in surgical visualization tools.
The R&D segment is expanding steadily due to increased exploration of ICG’s utility in photodynamic therapy and nanoparticle-based drug delivery systems.
2. By End-User
Hospitals are the largest consumers of Indocyanine Green globally. The growth of minimally invasive procedures and improvements in surgical equipment have increased the demand for Indocyanine Green in hospital settings. With healthcare expansion in emerging economies, hospital-based usage is expected to remain dominant.
Diagnostic centers are expanding their use of ICG for liver function tests, fluorescence angiography, and dynamic imaging techniques. As imaging centers proliferate in Asia-Pacific and the Middle East, this segment is seeing rapid growth.
Academic and research institutions contribute significantly to the Indocyanine Green sales volume through experimental use in biophotonics, tissue imaging, and drug delivery models. The increasing use of fluorescence dyes in molecular biology labs supports steady demand from this segment.
Pharmaceutical companies are exploring the use of Indocyanine Green in clinical trials, especially in drug localization studies and novel diagnostic test development. As regulatory authorities demand more imaging-based trial endpoints, this segment will grow steadily.
3. By Formulation
Lyophilized powder is the dominant formulation due to its longer shelf life and ease of reconstitution before use. This form is favored in hospitals and surgical centers that need high stability and accurate dosing.
Liquid formulations are used in situations requiring immediate application, especially in diagnostics and research. Although less common than powder, this segment is growing in diagnostic labs and short-cycle procedures.
4. By Purity Grade
Pharmaceutical grade dominates the market due to stringent requirements in diagnostic and surgical use. These variants are highly pure, sterile, and tested for endotoxins.
Research grade is less pure but sufficient for laboratory studies and preclinical trials. It is a growing segment due to increased university and institutional research.
Industrial grade is a niche category used in non-medical imaging or educational demonstrations but forms a very small portion of total sales.
5. By Geography
North America leads the global Indocyanine Green market due to high adoption in advanced diagnostics and surgical interventions. The U.S. is the top consumer, supported by strong healthcare infrastructure.
Europe follows closely with strong demand in Germany, France, and the UK. Regulatory standards and preference for high-quality imaging products fuel growth.
Asia-Pacific is the fastest-growing region. Countries like Japan, South Korea, and India are witnessing increased usage across hospitals and research labs. Growth in public healthcare investment is boosting regional demand.
Latin America and the Middle East & Africa are emerging markets. While volumes are lower, growth rates are strong due to increased diagnostic access, rising surgical volumes, and greater healthcare awareness.